Sammendrag
Immunotherapy is quickly changing the current cancer treatment paradigm and is becoming the future of cancer medicine. Although the field is promising, successful translation of basic research
findings from cancer biology, molecular biology and immunology to patient treatment and clinical trials requires a high-level infrastructure and brings new technical and scientific challenges. Successful
translation requires bridging of several gaps in knowledge, resources and competence.
* First, assessing the effect of new treatments on the immune system and explore combinations with the multitude of existing small molecule therapeutics is technically challenging and resource
intensive.
* Secondly, the complexity of immunotherapies makes it critical to confirm in vitro results in animal models, requiring specialized facilities and competence.
* Third, production of biologics is expensive and challenging and requires expertise in process development to optimise and up-scale initial low-yield and costly productions.
To bridge these gaps we now aim to adapt the leading research infrastructure and competence at SINTEF within high-throughput screening and process development to the unique challenges faced by
researchers in immunotherapy. These facilities are very well suited to venture into the field of immunotherapy, where we can address key elements of the human immune response to cancer and to
establish immunological methods in collaboration with academic and industrial partners.
findings from cancer biology, molecular biology and immunology to patient treatment and clinical trials requires a high-level infrastructure and brings new technical and scientific challenges. Successful
translation requires bridging of several gaps in knowledge, resources and competence.
* First, assessing the effect of new treatments on the immune system and explore combinations with the multitude of existing small molecule therapeutics is technically challenging and resource
intensive.
* Secondly, the complexity of immunotherapies makes it critical to confirm in vitro results in animal models, requiring specialized facilities and competence.
* Third, production of biologics is expensive and challenging and requires expertise in process development to optimise and up-scale initial low-yield and costly productions.
To bridge these gaps we now aim to adapt the leading research infrastructure and competence at SINTEF within high-throughput screening and process development to the unique challenges faced by
researchers in immunotherapy. These facilities are very well suited to venture into the field of immunotherapy, where we can address key elements of the human immune response to cancer and to
establish immunological methods in collaboration with academic and industrial partners.